Kazempour's stance is, Cytodyn can (and has always

Kazempour's stance is, Cytodyn can (and has always been able to) access the data from the clinical sites.
Cytodyn wants the database, which is in EDC format. Their point is, they paid for the information to be put into a format that they can work with. They paid for processed data, not the raw data (available from the clinical sites).
Kazempour's stance is, that he created the EDC program. It is proprietary to Amarex. To access the data, in EDC format, they have to have the program. The contract cannot require him to provide the program to Cytodyn.
This is a very muddled mess. Can you imagine any biomedical/pharmaceutical company that would want to do business with an entity that could/would do this to them. All of the bashers are preaching that Cytodyn is operating from a position of weakness (because they have let it go on so long, without complaint). Personally, if I was with NSF, I am thinking that Amarex is a huge liability. This could terminally damage their business. They need to get get this handled as quickly and quietly as possible. This is the kind of case that Sidley Austin is famous for.